Company news
Zhuzhou Qianjin Pharmaceutical Co., Ltd. Class A (SSE:600479) news
Zhuzhou Qianjin Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 29, 2026: "Zhuzhou Qianjin Pharmaceutical Co., Ltd."Announcement…
Press releases & updates
"Zhuzhou Qianjin Pharmaceutical Co., Ltd."Announcement on Resignation of Director
September 28, 2026
"Zhuzhou Qianjin Pharmaceutical Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading
September 11, 2026
"Zhuzhou Qianjin Pharmaceutical Co., Ltd."Announcement on Risk Warning in Stock Trading
August 28, 2026
"Zhuzhou Qianjin Pharmaceutical Co., Ltd."Announcement on Resolutions of the 17th Meeting of the 11th Board of Directors
August 25, 2026
"Zhuzhou Qianjin Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate by Subsidiary
August 17, 2026
"Zhuzhou Qianjin Pharmaceutical Co., Ltd."Announcement on the Proposed Selection of the Company's Products in the 12th Batch of National Centralized Drug Procurement
August 3, 2026
"Zhuzhou Qianjin Pharmaceutical Co., Ltd."Announcement on Acquisition of Drug Registration Certificate by Subsidiaries
July 20, 2026
"Zhuzhou Qianjin Pharmaceutical Co., Ltd."Announcement on Change of Independent Financial Advisor Sponsor for Continuous Supervision
July 16, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 23, 2026
Announcement on Obtaining Drug Registration Certificate by Subsidiary
June 16, 2026
Announcement on Outline of the Performance Briefing for 2025 and Q1 2026
June 15, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
June 3, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 22, 2026
Announcement on Obtaining Drug Registration Certificate by the Company and Its Subsidiary
May 19, 2026
Announcement on Achievement of 2025 Performance Commitment on Purchasing Asset through Shares Issuance and Cash Payment and Related Party Transactions
April 28, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 9, 2026
Announcement on Resignation of Director and Election of Employee Director
February 5, 2026
Announcement on the Approval of Buoxue Yimu Pill as a National Protected Traditional Chinese Medicine Variety
January 21, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
January 12, 2026
Announcement on Resolutions of the 15th Meeting of the 11th Board of Directors
December 19, 2025
Announcement on Changing the Independent Financial Advisor for Continuous Supervision
December 12, 2025
Announcement on Profit and Loss during Transition Period of Underlying Assets Related to the Company's Issuance of Shares and Payment of Cash to Purchase Assets and Related Party Transactions
December 10, 2025
Announcement on Outline of the Q3 2025 Performance Briefing
November 20, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
November 17, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 14, 2025
Announcement on Main Operating Data for Q3 2025
October 29, 2025
Announcement on the Implementation of Issuance of Shares and Payment in Cash for Asset Purchase and Related Party Transactions and Changes in Capital Shares
October 27, 2025
Announcement on Amendment to Report on Purchasing Assets through Issuance of Shares and Cash Payment and Related Party Transaction
September 22, 2025
Announcement on Transfer of Underlying Assets Related to the Company's Issuance of Shares and Payment of Cash to Purchase Assets and Related Party Transactions
September 17, 2025
Announcement on Obtaining Registration Approval from the China Securities Regulatory Commission for Issuance of Shares and Cash Payment for Asset Acquisition and Related Party Transactions
September 12, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Hunan Jurisdiction and Semi-annual Performance Briefing
September 11, 2025
2025 Semi-annual Report
August 29, 2025
Announcement on the Approval by the M&A and Restructuring Review Committee of the Shanghai Stock Exchange of the Issuance of Shares and Payment of Cash to Purchase Assets through Related Party Transactions
August 19, 2025
Announcement on the Meeting Arrangement of the Shanghai Stock Exchange M&A and Restructuring Review Committee for the Review of the Company's Proposed Issuance of Shares and Payment of Cash to Purchase Assets and Related Party Transactions
August 12, 2025
Announcement on Amendment to Report on Purchasing Assets through Issuance of Shares and Cash Payment and Related Party Transaction (Draft) (Revised Edition)
August 7, 2025
Announcement on Implementation of Dividend Distribution for 2024
July 17, 2025
Announcement on Implementation of Repurchasing and Canceling Restricted Stocks
July 7, 2025
Indicative Announcement on Reply Update to the Review Inquiry Letter of Application for Purchasing Assets by Issuing Shares and Paying Cash and Related Party Transactions
July 4, 2025
Announcement on Outline of the 2024 Annual and Q1 2025 Performance Briefing
June 18, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
June 10, 2025
Indicative Announcement on Reply to the Review Inquiry Letter of Application for Purchasing Assets by Issuing Shares and Paying Cash and Related Party Transactions
June 6, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 29, 2025
Announcement on Provision of Online Voting Reminder Service for General Meeting
May 22, 2025
Notice on the 2024 Annual General Meeting
April 28, 2025
Announcement on Resignation of Director
April 18, 2025
Announcement on Acceptance of Application for Purchasing Assets by Issuing Shares and Paying Cash and Related Transactions by Shanghai Stock Exchange
April 1, 2025
Announcement on Changing Signatory Certified Public Accountant
March 19, 2025
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025
March 14, 2025
Announcement on Release of Pledge of Some Shares of Controlling Shareholders
February 28, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
February 24, 2025